NASDAQ$ABUS
Arbutus Biopharma Corp · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Arbutus reported its fourth quarter and year end 2021 financial results and provided a corporate update.
Arbutus Biopharma Corporation reported its Q4 and year end 2021 financial results, highlighting the expansion of development efforts in Hepatitis B and coronavirus infections. The company anticipates reporting data from four clinical trials in chronically infected HBV patients in 2022 and expects to complete IND-enabling studies for two oral compounds to treat HBV in the second half of 2022.
- Expanded development efforts in Hepatitis B and coronavirus infections.
- Formed strategic and clinical partnerships to explore combination therapies with AB-729.
- Expanded preclinical programs in HBV with oral PD-L1 inhibitor AB-101 and oral RNA destabilizer AB-161.
- Multiple key clinical trial data read-outs expected later this year for AB-729 and AB-836.
Headline financials
Revenue & EPS history
Arbutus · Revenue · Quarterly
$3.21M
Revenue by segment
Arbutus · $689K total across 1 segment · Q2 2020
- Non-cash Royalty Revenue$689K—100.0%
Forward guidance
Arbutus anticipates reporting data from four clinical trials in chronically infected HBV patients in 2022 and expects to complete IND-enabling studies for two oral compounds to treat HBV in the second half of 2022. The company expects a net cash burn between $90 to $95 million in 2022 and believes its cash runway will be sufficient to fund the Company’s operations into the second quarter of 2024.
Tailwinds
- Reporting data from four clinical trials in chronically infected HBV patients in 2022
- Completing IND-enabling studies for two oral compounds (PD-L1 inhibitor AB-101 and RNA destabilizer AB-161) to treat HBV in the second half of 2022
- Advancing an oral compound that inhibits the SARS-CoV-2 nsp5 main protease into IND enabling studies in the second half of 2022
- Cash runway sufficient to fund the Company’s operations into the second quarter of 2024
- Strategic partnership to develop and commercialize AB-729 in China
Headwinds
- Net cash burn between $90 to $95 million in 2022
- COVID-19 pandemic could materially impact plans and timelines in the future
- Anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated
- Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products
- Economic and market conditions may worsen
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-1.3%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-0.4%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+22.2%
Q1 2020
Best reaction
-18.6%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -3.2% | — | |
| Q4 2025 | +4.2% | +1.2% | +4.5% | |
| Q3 2025 | -5.8% | -8.1% | -2.7% | |
| Q1 2025 | -0.9% | -1.9% | +10.7% | |
| Q4 2024 | -2.4% | +3.9% | -1.8% | |
| Q3 2024 | -5.8% | -5.8% | -7.1% | |
| Q2 2024 | -0.8% | -4.0% | +2.7% | |
| Q1 2024 | +0.7% | +5.6% | +24.9% | |
| Q4 2023 | -3.1% | -7.3% | -10.4% | |
| Q3 2023 | -0.5% | -5.9% | +10.6% | |
| Q2 2023 | +2.9% | -2.4% | -1.4% | |
| Q1 2023 | +3.6% | +4.0% | +2.8% | |
| Q4 2022 | +1.8% | +4.3% | +7.8% | |
| Q3 2022 | +0.8% | +7.3% | +6.1% | |
| Q2 2022 | +2.8% | +0.0% | -10.2% | |
| Q1 2022 | +1.6% | -20.5% | +8.4% | |
| Q4 2021 | -9.1% | -6.8% | -0.3% | |
| Q3 2021 | -9.6% | -9.1% | +7.8% | |
| Q2 2021 | +9.1% | +13.8% | +23.6% | |
| Q1 2021 | -15.9% | -20.4% | -11.7% | |
| Q4 2020 | -9.3% | -1.1% | -5.8% | |
| Q3 2020 | -8.8% | +5.9% | +31.0% | |
| Q2 2020 | -16.2% | -18.5% | -44.2% | |
| Q1 2020 | +22.2% | +55.6% | +37.0% | |
| Q4 2019 | -2.0% | -8.3% | -70.0% | |
| Q3 2019 | -4.0% | -3.4% | +53.7% | |
| Q2 2019 | +1.2% | +1.2% | -11.0% | |
| Q1 2019 | -5.4% | -10.0% | -36.4% | |
| Q4 2018 | -8.0% | +2.7% | +9.5% | |
| Q3 2018 | +13.7% | -6.7% | -7.4% | |
| Q2 2018 | -18.6% | -19.4% | -23.2% | |
| Q1 2018 | +3.5% | +8.8% | +7.0% | |
| Q4 2017 | -12.5% | -17.5% | -13.3% | |
| Q3 2017 | +20.4% | +4.6% | +2.8% | |
| Q2 2017 | -4.2% | +1.4% | +15.3% | |
| Q1 2017 | -2.4% | -0.9% | +2.1% | |
| Q4 2016 | -6.0% | -4.5% | +0.0% | |
| Q3 2016 | -3.3% | -4.9% | -12.1% | |
| Q2 2016 | -8.6% | -13.6% | -14.5% | |
| Q1 2016 | -3.8% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -2.3% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -5.1% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2013 | -3.1% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +0.6% | — | — | |
| Q2 2012 | -0.3% | — | — | |
| Q1 2012 | -5.1% | — | — | |
| Q4 2011 | +2.9% | — | — | |
| Q4 2010 | +2.9% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | -4.1% | — | — | |
| Q3 2010 | +0.8% | — | — | |
| Q2 2010 | -0.8% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro